IL133225A - (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders - Google Patents

(+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders

Info

Publication number
IL133225A
IL133225A IL13322598A IL13322598A IL133225A IL 133225 A IL133225 A IL 133225A IL 13322598 A IL13322598 A IL 13322598A IL 13322598 A IL13322598 A IL 13322598A IL 133225 A IL133225 A IL 133225A
Authority
IL
Israel
Prior art keywords
norcisapride
useful
mediated disorders
intestinal disorders
treating gastro
Prior art date
Application number
IL13322598A
Other languages
English (en)
Other versions
IL133225A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL133225A0 publication Critical patent/IL133225A0/xx
Publication of IL133225A publication Critical patent/IL133225A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13322598A 1997-07-11 1998-07-07 (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders IL133225A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97202161 1997-07-11
EP98200661 1998-03-04
PCT/EP1998/004193 WO1999002496A1 (en) 1997-07-11 1998-07-07 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders

Publications (2)

Publication Number Publication Date
IL133225A0 IL133225A0 (en) 2001-03-19
IL133225A true IL133225A (en) 2005-12-18

Family

ID=26146686

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13322598A IL133225A (en) 1997-07-11 1998-07-07 (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders

Country Status (30)

Country Link
US (2) US20030060485A1 (cs)
EP (1) EP1000029B1 (cs)
JP (1) JP3529102B2 (cs)
KR (1) KR100358374B1 (cs)
CN (1) CN1196681C (cs)
AT (1) ATE251139T1 (cs)
AU (1) AU757077B2 (cs)
BG (1) BG64824B1 (cs)
BR (1) BR9811676A (cs)
CA (1) CA2292480A1 (cs)
CO (1) CO4940432A1 (cs)
CZ (1) CZ296212B6 (cs)
DE (1) DE69818678T2 (cs)
DK (1) DK1000029T3 (cs)
EA (1) EA002362B1 (cs)
EE (1) EE04491B1 (cs)
ES (1) ES2209190T3 (cs)
HR (1) HRP20000004A2 (cs)
HU (1) HUP0003078A3 (cs)
ID (1) ID24228A (cs)
IL (1) IL133225A (cs)
MY (1) MY129130A (cs)
NO (1) NO315183B1 (cs)
NZ (1) NZ502207A (cs)
PL (1) PL190296B1 (cs)
PT (1) PT1000029E (cs)
SK (1) SK284941B6 (cs)
TR (1) TR200000020T2 (cs)
TW (1) TW553934B (cs)
WO (1) WO1999002496A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
SI1089733T1 (en) 1998-06-15 2005-06-30 Sepracor Inc. Use of optically pure (+)-norcisapride for treating irritable bowel syndrome
TR200003707T2 (tr) * 1998-06-15 2001-06-21 Sepracor Inc. Apne , bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
HK1044277B (en) * 1999-08-03 2014-02-28 Icos Corporation Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
WO2001093849A2 (en) * 2000-06-07 2001-12-13 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
JP2004513969A (ja) * 2000-11-24 2004-05-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 腸洗浄を促進するための5ht3アンタゴニスト、5ht4アゴニスト及び緩下薬を含んでなる三種類の組み合わせの使用
CA2463168A1 (en) * 2001-10-08 2003-04-17 Sun Pharmaceutical Industries Limited An antispasmodic agent spaced drug delivery system
JP2003342186A (ja) * 2002-05-24 2003-12-03 Taisho Pharmaceut Co Ltd 鼻炎用内服液剤組成物
US8138204B2 (en) 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
BRPI0506736B1 (pt) 2004-01-07 2018-08-21 Renexxion Llc Compostos estereoisoéricos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central, e composições
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20060247180A1 (en) * 2005-04-29 2006-11-02 Bergey James L Purgative composition and uses thereof
ES2436100T3 (es) 2005-08-31 2013-12-27 Armetheon, Inc. Métodos sintéticos y productos intermedios para compuestos estereoisoméricos útiles para el tratamiento de trastornos del sistema nervioso central y gastrointestinal
KR20100026641A (ko) * 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
AU2018302170B2 (en) * 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
JP2021530494A (ja) * 2018-07-11 2021-11-11 デューク・ユニヴァーシティ 胃腸障害の治療における徐放性5−ヒドロキシトリプトファンの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
IL89848A (en) * 1988-04-07 1997-08-14 Sepracor Chiral ester derivatives
TW213460B (cs) * 1991-02-15 1993-09-21 Hokuriku Pharmaceutical
TW294595B (cs) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
FR2717174B1 (fr) * 1994-03-14 1996-05-31 Sanofi Sa Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease

Also Published As

Publication number Publication date
WO1999002496A1 (en) 1999-01-21
CZ461799A3 (cs) 2000-05-17
US20030060485A1 (en) 2003-03-27
EA002362B1 (ru) 2002-04-25
NO20000093L (no) 2000-03-10
KR100358374B1 (ko) 2002-10-25
CA2292480A1 (en) 1999-01-21
NO20000093D0 (no) 2000-01-07
DE69818678T2 (de) 2004-07-15
SK182999A3 (en) 2000-08-14
CN1196681C (zh) 2005-04-13
EP1000029B1 (en) 2003-10-01
BR9811676A (pt) 2000-09-19
HUP0003078A2 (hu) 2001-01-29
TW553934B (en) 2003-09-21
EE04491B1 (et) 2005-06-15
SK284941B6 (sk) 2006-02-02
CN1262675A (zh) 2000-08-09
BG64824B1 (bg) 2006-05-31
ES2209190T3 (es) 2004-06-16
EE200000014A (et) 2000-10-16
DK1000029T3 (da) 2004-02-23
CO4940432A1 (es) 2000-07-24
JP2000515560A (ja) 2000-11-21
NO315183B1 (no) 2003-07-28
KR20010014027A (ko) 2001-02-26
MY129130A (en) 2007-03-30
TR200000020T2 (tr) 2000-09-21
EP1000029A1 (en) 2000-05-17
BG103934A (en) 2000-11-30
AU757077B2 (en) 2003-01-30
NZ502207A (en) 2001-08-31
HK1025092A1 (en) 2000-11-03
AU8857598A (en) 1999-02-08
US20040176414A1 (en) 2004-09-09
EA200000057A1 (ru) 2000-08-28
PL337648A1 (en) 2000-08-28
JP3529102B2 (ja) 2004-05-24
HUP0003078A3 (en) 2002-02-28
ID24228A (id) 2000-07-13
PL190296B1 (pl) 2005-11-30
PT1000029E (pt) 2004-02-27
ATE251139T1 (de) 2003-10-15
HRP20000004A2 (en) 2000-12-31
DE69818678D1 (de) 2003-11-06
CZ296212B6 (cs) 2006-02-15
IL133225A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
IL133225A (en) (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
UA29476C2 (uk) Трансдермальна терапевтична система, що містить естрадіол
RO116900B1 (ro) Derivaţi de dihidrobenzopiran, procedeu pentru prepararea acestora, intermediar pentru realizarea procedeului, compoziţie farmaceutică şi metodă de tratament
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
ZA961074B (en) Chiral Methylphenyloxazolidinones.
UA19782A (uk) Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей
MY116593A (en) Process for the preparation of o-demethyltramadol enantiomers
AU2102497A (en) Resolution of threo-methylphenidate
SI1274685T1 (sl) Derivat piridin-1-oksida in postopek njegove transformacije v farmacevtsko ucinkovite sestavine
GR3024592T3 (en) Process for preparing and resolving 2-phenyl-3-aminopiperidine
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
AU6851396A (en) Novel fused isoquinolines as dopamine receptor ligands
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
IL128028A0 (en) Treatment of psychotic disorders
EP0804186A4 (en) INDOLDITERPEN ALKALOIDS
ZA973156B (en) Process for the production of enantiomerically-pure azetidine-2-carboxylic acid.
IL122708A0 (en) Process for the production of enantiomerically-pure azetidine-2-carboxylic acid
MY101747A (en) Dihydroorotic acids derivative, processes for preparing the same
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
AU2788984A (en) 4-oxothiazolidin-2-ylidene-acetamide derivatives
PL352119A1 (en) Derivatives of aminotetraline for treatment of cardiovascular diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees